In my Is Merck a Good Stock to Buy? guest post published on January 13, 2022 at Dividend Power, I share my thoughts on why investors may no longer want to look at MRK through the same lens as in the past.
The current Merck & Co., Inc. (MRK) is much different from that with which many investors may be familiar. The company now aspires to be the premier research-intensive biopharmaceutical company and no longer has the steady/reliable slow growth women’s health, trusted legacy brands and biosimilars businesses.
I think the direction it has taken makes it a company that presents the opportunity for growth that is superior to historical levels. In exchange for this higher growth potential, however, is slightly higher risk.
I wish you much success on your journey to financial freedom!
Note: Please send any feedback, corrections, or questions to [email protected].
Disclosure: I am long MRK in an account held within the FFJ Portfolio.
Disclaimer: I do not know your circumstances and do not provide individualized advice or recommendations. I encourage you to make investment decisions by conducting your research and due diligence. Consult your financial advisor about your specific situation.
I wrote this article myself and it expresses my own opinions. I do not receive compensation for it and have no business relationship with any company mentioned in this article.
